Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

被引：0
|
作者：
Fizazi, K. [1 ]
Luz, M. [2 ]
Ulys, A. [3 ]
Ortiz, J. [4 ]
Srinivasan, S. [5 ]
Kurland, E. [6 ]
Shore, N. D. [7 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France
[2] Hosp Erasto Gaertner, Dept Urol, Curitiba, Parana, Brazil
[3] Vilnius Univ, Inst Oncol, Vilnius, Lithuania
[4] Bayer HealthCare, Dept Med Affairs, Whippany, NJ USA
[5] Bayer HealthCare, Dept Stat, Whippany, NJ USA
[6] Bayer HealthCare, Clin Dev, Whippany, NJ USA
[7] Carolina Urol Res Ctr & Genesis Care, Dept Urol, Atlant Urol, Myrtle Beach, SC USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A1193
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TREATMENT DURATION AND LONG-TERM SAFETY AND TOLERABILITY WITH DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): ARAMIS ROLLOVER STUDY
    Shore, Neal D.
    Luz, Murilo
    Ulys, Albertas
    Ortiz, Jorge
    Srinivasan, Shankar
    Kurland, Etah
    Fizazi, Karim
    JOURNAL OF UROLOGY, 2023, 209 : E129 - E130
  • [2] Long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS Rollover Study.
    Shore, Neal D.
    Luz, Murilo de Almeida
    Ulys, Albertas
    Ortiz, Jorge A.
    Srinivasan, Shankar
    Kurland, Etah
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris Y.
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 2 - 5
  • [5] DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Armstrong, Andrew J.
    Suzuki, Hiroyoshi
    Bailen, James L.
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Khan, Javeed
    Briganti, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17029 - E17029
  • [6] Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
    Shore, Neal D.
    Gratzke, Christian
    Feyerabend, Susan
    Werbrouck, Patrick
    Carles, Joan
    Vjaters, Egils
    Tammela, Teuvo L. J.
    Morris, David
    Aragon-Ching, Jeanny B.
    Concepcion, Raoul S.
    Emmenegger, Urban
    Fleshner, Neil
    Grabbert, Markus
    Lietuvietis, Vilnis
    Mahammedi, Hakim
    Cruz, Felipe M.
    Paula, Adriano
    Pieczonka, Christopher
    Rannikko, Antti
    Richardet, Martin
    Silveira, Glauco
    Kuss, Iris
    Le Berre, Marie-Aude
    Verholen, Frank
    Sarapohja, Toni
    Smith, Matthew R.
    Fizazi, Karim
    ONCOLOGIST, 2024, 29 (07): : 581 - 588
  • [7] DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Briganti, Alberto
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Suzuki, Hiroyoshi
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Guan, Rongjin
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
    Carles, Joan
    Medina-Lopez, Rafael A.
    Puente, Javier
    Gomez-Ferrer, Alvaro
    Nebra, Javier Casas
    Medina, Maria Isabel Saez
    Ribal, Maria J.
    Antolin, Alfredo Rodriguez
    Alvarez-Ossorio, Jose Luis
    Novo, Jose Francisco Suarez
    Agut, Cristina Moretones
    Srinivasan, Shankar
    Ortiz, Jorge
    Fizazi, Karim
    FUTURE ONCOLOGY, 2023, 19 (12) : 819 - 828
  • [9] Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
    Pang, J. S-T.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M-A.
    Snapir, A.
    Sarapohja, T.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
    Smith, M. R.
    Shore, N. D.
    Tammela, T. L. J.
    Le Berre, M-A.
    Petrenciuc, O.
    Zurth, C.
    Kuss, I.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1327 - S1328
12345